糖化血红蛋白变异指数与糖尿病慢性并发症发生风险的相关性研究

doi:10.12114/j.issn.1007-9572.2019.00.523

摘要/Abstract

摘要： 背景　糖化血红蛋白变异指数（HGI）作为一种简单易行的衡量血红蛋白糖化程度的指标，与糖尿病微血管和大血管并发症之间的独立相关性在国外研究中已有报道，但在亚洲人群中研究尚不全面。目的　分析中国南京市某社区人群HGI与多种糖尿病慢性并发症（糖尿病肾病、糖尿病视网膜病变、糖尿病足、糖尿病神经病变）之间的关联性，探讨HGI在糖尿病慢性并发症发病风险预测中的作用。方法　收集2015年4月—2018年1月于南京市某社区医院糖尿病专案管理的644例糖尿病患者的临床资料，计算HGI。将患者按照HGI三分位数法分为低HGI组（HGI≤-0.313%）、中HGI组（-0.313%<HGI≤0.160%）和高HGI组（HGI>0.160%），进而评估不同HGI水平与糖尿病慢性并发症发生风险的关系。结果　本研究糖尿病足患者仅8例，因此本研究将其他几种并发症的患病情况作为因变量纳入多因素Logistic回归分析。调整年龄、性别、饮酒史、糖尿病分型、BMI、高血压、高脂血症、冠心病、糖化血红蛋白（HbA1c）后的多因素Logistic回归分析显示，与低HGI组相比，高HGI组的糖尿病患者发生糖尿病慢性并发症〔调整OR=2.576，95%CI（1.077，6.164），P=0.033〕，尤其是糖尿病肾病〔调整OR=3.402，95%CI（1.070，10.817），P=0.038〕的风险增高，未发现HGI与糖尿病视网膜病变、糖尿病神经病变之间存在关联性（P>0.05）。结论　高HGI水平的糖尿病患者可能更易发生糖尿病慢性并发症尤其是糖尿病肾病，HGI检测有望用于临床上糖尿病患者并发糖尿病肾病等并发症的个性化风险评估和预测。

关键词: 糖尿病；糖尿病并发症；血红蛋白A, 糖基化；糖化血红蛋白变异指数；糖尿病肾病

Abstract: Background　HbA1c glycation index（HGI） is a simply and conveniently measured indicator that reflects the level of glycosylated hemoglobin.Its associations with microvascular and macrovascular complications of diabetes have been reported in foreign studies，but have not been well studied in Asian.Objective　To investigate the value of HGI in predicting chronic complications of diabetes by examining its associations with multiple chronic complications of diabetes（diabetic nephropathy，diabetic retinopathy，diabetic foot，diabetic neuropathy） in populations from a community of Nanjing，China.Methods　Clinical data of 644 diabetic patients who received services from a diabetes management project of a community hospital，Nanjing from April 2015 to January 2018 were collected.Based on the calculated HGI level，they were divided into low HGI group（tertile 1：HGI≤-0.313%），medium HGI group（tertile 2：-0.313%<HGI≤0.160%），and high HGI group（tertile 3：HGI>0.160%）.Association of HGI and the risk of chronic complications of diabetes was estimated.Results　As the sample size of diabetic foot （only 8 cases） was too small，so only the prevalence rates of other three complications were incorporated in the multivariate Logistic regression model as dependent variables.After adjusting for age，sex，history of alcohol consumption，type of diabetes，BMI，hypertension，hyperlipidemia，coronary heart disease，and HbA1c，Logistic regression analysis showed that high HGI group had a significantly increased risk of chronic diabetic complications〔adjusted OR=2.576，95%CI（1.077，6.164），P=0.033〕，and showed an even higher risk of diabetic nephropathy〔adjusted OR=3.402，95%CI（1.070，10.817），P=0.038〕 compared with low HGI group.But no significant associations of HGI with the risk of diabetic retinopathy and diabetic neuropathy were found（P>0.05）.Conclusion　The patients with high HGI may be more likely to develop chronic diabetic complications，especially diabetic nephropathy.HGI measurement is expected to be used for personalized assessment and prediction of diabetic nephropathy in diabetic patients in clinic practice.

Key words: Diabetes mellitus；Diabetes complications；Hemoglobin A, glycosylated；Hemoglobin glycation index；Diabetic nephropathies

钟玉玲,凡豪志,张茹,等. 糖化血红蛋白变异指数与糖尿病慢性并发症发生风险的相关性研究[J]. 中国全科医学, 2020, 23(3): 276-280. DOI: 10.12114/j.issn.1007-9572.2019.00.523.
ZHONG Yuling,FAN Haozhi,ZHANG Ru, et al. Associations between HbA1c Glycation Index and Risk of Chronic Complications of Diabetes Mellitus　[J]. Chinese General Practice, 2020, 23(3): 276-280. DOI: 10.12114/j.issn.1007-9572.2019.00.523.

参考文献

［1］International Diabetes Ferderation（IDF）.IDF Diabetes Atlas （Eighth edition 2017）［EB/OL］．［2019-01-20］.http：//www.diabetesatlas.org.
［2］NCD Risk Factor Collaboration （NCD-RISC）.Worldwide trends in diabetes since 1980：a pooled analysis of 751 population-based studies with 4.4 million participants［J］．Lancet，2016，387（10027）：1513-1530．DOI：10.1016/S0140-6736（16）00618-8.
［3］CHAMBERLAIN J J，RHINEHART A S，SHAEFER C F Jr，et al．Diagnosis and management of diabetes：synopsis of the 2016 American diabetes association standards of medical care in diabetes［J］．Ann Intern Med，2016，164（8）：542．DOI：10.7326/m15-3016.
［4］GILLETT M J.International expert committee report on the role of the A1c assay in the diagnosis of diabetes：diabetes care 2009；32（7）：1327-1334［J］．Clin Biochem Rev，2009，30（4）：197-200.
［5］NATHAN D M，TURGEON H，REGAN S.Relationship between glycated haemoglobin levels and mean glucose levels over time［J］．Diabetologia，2007，50（11）：2239-2244．DOI：10.1007/s00125-007-0803-0.
［6］MARINI M A，FIORENTINO T V，SUCCURRO E，et al．Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals［J］．PLoS One，2017，12（4）：e0175547．DOI：10.1371/journal.pone.0175547.
［7］HERMAN W H，MA Y，UWAIFO G，et al．Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program［J］．Diabetes Care，2007，30（10）：2453-2457．DOI：10.2337/dc06-2003.
［8］SOROS A A，CHALEW S A，MCCARTER R J，et al．Hemoglobin glycation index：a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients［J］．Pediatr Diabetes，2010，11（7）：455-461．DOI：10.1111/j.1399-5448.2009.00630.x.
［9］HEMPE J M，GOMEZ R，MCCARTER R J Jr，et al．High and low hemoglobin glycation phenotypes in type 1 diabetes：a challenge for interpretation of glycemic control［J］．J Diabetes Complicat，2002，16（5）：313-320.
［10］HEMPE J M，LIU S Q，MYERS L，et al．The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial［J］．Diabetes Care，2015，38（6）：1067-1074．DOI：10.2337/dc14-1844.
［11］GENUTH S，LACHIN J M，NATHAN D M.Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes：response to McCarter et al［J］．Diabetes Care，2005，28（1）：233；author reply 234-233；author reply 234-5．DOI：10.2337/diacare.28.1.233.
［12］WHO.Definition，Diagnosis，and Classification of Diabetes.Diagnosis & Classification of Diabetes Mellitus 1999［EB/OL］．
［2019-01-20］.https：//www.staff.ncl.ac.uk/philip.home/who_dmc.htm.
［13］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2010年版）［J］．中国医学前沿杂志：电子版，2011，3（6）：54-109．DOI：10.3969/j.issn.1674-7372.2011.06.014.
［14］American Diabetes Association.11.microvascular complications and foot care：standards of medical care in diabetes-2019［J］．Diabetes Care，2019，42（Suppl 1）：S124-138．DOI：10.2337/dc19-S011.
［15］AHN J H，YU J H，KO S H，et al．Prevalence and determinants of diabetic nephropathy in Korea：Korea national health and nutrition examination survey［J］．Diabetes Metab J，2014，38（2）：109-119．DOI：10.4093/dmj.2014.38.2.109.
［16］TUTTLE K R，BAKRIS G L，BILOUS R W，et al．Diabetic kidney disease：a report from an Ada consensus conference［J］．Diabetes Care，2014，37（10）：2864-2883．DOI：10.2337/dc14-1296.
［17］KILPATRICK E S，RIGBY A S，ATKIN S L.A1C variability and the risk of microvascular complications in type 1 diabetes：data from the Diabetes Control and Complications Trial［J］．Diabetes Care，2008，31（11）：2198-2202．DOI：10.2337/dc08-0864.
［18］WADéN J，FORSBLOM C，THORN L M，et al．A1C variability predicts incident cardiovascular events，microalbuminuria，and overt diabetic nephropathy in patients with type 1 diabetes［J］．Diabetes，2009，58（11）：2649-2655．DOI：10.2337/db09-0693.
［19］HEMPE J M，GOMEZ R，MCCARTER R J Jr，et al．High and low hemoglobin glycation phenotypes in type 1 diabetes：a challenge for interpretation of glycemic control［J］．J Diabetes Complicat，2002，16（5）：313-320.
［20］RODRíGUEZ-SEGADE S，RODRíGUEZ J，CABEZAS-AGRICOLA J M，et al．Progression of nephropathy in type 2 diabetes：the glycation gap is a significant predictor after adjustment for glycohemoglobin （Hb A1c）［J］．Clin Chem，2011，57（2）：264-271．DOI：10.1373/clinchem.2010.144949.
［21］KOVATCHEV B，COBELLI C.Glucose variability：timing，risk analysis，and relationship to hypoglycemia in diabetes［J］．Diabetes Care，2016，39（4）：502-510．DOI：10.2337/dc15-2035.
［22］CERIELLO A，COLAGIURI S.International diabetes federation guideline for management of postmeal glucose：a review of recommendations［J］．Diabet Med，2008，25（10）：1151-1156．DOI：10.1111/j.1464-5491.2008.02565.x.
［23］ZHAO Q，ZHOU F，ZHANG Y S，et al．Fasting plasma glucose variability levels and risk of adverse outcomes among patients with type 2 diabetes：a systematic review and meta-analysis［J］．Diabetes Res Clin Pract，2019，148：23-31．DOI：10.1016/j.diabres.2018.12.010.
［24］KIM M K，JEONG J S，YUN J S，et al．Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus：a 10-year longitudinal cohort study［J］．J Diabetes Complicat，2018，32（10）：906-910．DOI：10.1016/j.jdiacomp.2018.08.007.
［25］CHENG P C，HSU S R，CHENG Y C，et al．Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus：a cross-sectional study［J］．Peer J，2017，5：e3875．DOI：10.7717/peerj.3875.
［26］FIORENTINO T V，MARINI M A，SUCCURRO E，et al．Elevated hemoglobin glycation index identify non-diabetic individuals at increased risk of kidney dysfunction［J］．Oncotarget，2017，8（45）：79576-79586．DOI：10.18632/oncotarget.18572.
［27］KOSKA J，SAREMI A，HOWELL S，et al．Advanced glycation end products，oxidation products，and incident cardiovascular events in patients with type 2 diabetes［J］．Diabetes Care，2018，41（3）：570-576．DOI：10.2337/dc17-1740.
［28］RABBANI N，THORNALLEY P J.Advanced glycation end products in the pathogenesis of chronic kidney disease［J］．Kidney Int，2018，93（4）：803-813．DOI：10.1016/j.kint.2017.11.034.
［29］HOFMANN B，ADAM A C，JACOBS K，et al．Advanced glycation end product associated skin autofluorescence：a mirror of vascular function?［J］．Exp Gerontol，2013，48（1）：38-44．DOI：10.1016/j.exger.2012.04.011.
［11］BORLAUG B A，KANE G C，MELENOVSKY V，et al．Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction［J］．Eur Heart J，2016，37（43）：3293-3302．DOI：10.1093/eurheartj/ehw241.
［12］VAN HEEREBEEK L，PAULUS W J.Understanding heart failure with preserved ejection fraction：where are we today?［J］．Neth Heart J，2016，24（4）：227-236．DOI：10.1007/s12471-016-0810-1.
［13］THOMPSON R B，PAGANO J J，CHOW K，et al．Subclinical pulmonary edema is associated with reduced exercise capacity in HFpEF and HFrEF［J］．J Am Coll Cardiol，2017，70（14）：1827-1828．DOI：10.1016/j.jacc.2017.07.787.
［14］梁峰，胡大一，方全，等．左室射血分数保留的心力衰竭［J］．中国循证心血管医学杂志，2015，7（5）：706-709．DOI：10.3969/j.issn.1674-4055.2015.05.42.
［15］寇威，薛永亮，刘晓琰，等．左室射血分数保留心力衰竭患者加用螺内酯治疗一例［J］．中国实用医刊，2017，44（14）：125-126．DOI：10.3760/cma.j.issn.1674-4756.2017.14.041.
［16］TROMP J，KHAN M A，KLIP I T，et al．Biomarker profiles in heart failure patients with preserved and reduced ejection fraction［J］．J Am Heart Assoc，2017，6（4）：e003989．DOI：10.1161/JAHA.116.003989.
［17］PITT B，PFEFFER M A，ASSMANN S F，et al．Spironolactone for heart failure with preserved ejection fraction［J］．N Engl J Med，2014，370（15）：1383-1392．DOI：10.1056/NEJMoa1313731.
［18］秦榕蔚，陈茉，黄花.射血分数保留心力衰竭患者血清半乳糖凝集素-3水平变化及意义［J］．中国循证心血管医学杂志，2018，10（8）：957-960．DOI：10.3969/j.issn.1674-4055.2018.08.17.
QIN R W，CHEN M，HUANG H.Changes and significance of serum galectin-3 level in patients with heart failure with preserved ejection fraction［J］．Chinese Journal of Evidence-Bases Cardiovascular Medicine，2018，10（8）：957-960．DOI：10.3969/j.issn.1674-4055.2018.08.17.
［19］李丹，童嘉毅.射血分数保留心衰相关肺高压及其危险因素［J］．现代医学，2017，45（6）：890-894.
［20］石衍梅，尉若川，李虹.左室射血分数保留心衰的研究进展［J］．中西医结合心脑血管病杂志，2016，14（15）：1744-1746．DOI：10.3969/j.issn.1672-1349.2016.15.015.